Brief: Novozymes Says 2024 Outlook Of Pro Forma Organic Sales Growth Now Expected At Upper End Of 5-7% Range
June 17 (Reuters) - Novozymes A/S NSISb.CO :
* 2024 OUTLOOK OF PRO FORMA ORGANIC SALES GROWTH NOW
EXPECTED AT
UPPER END OF 5-7% RANGE
* FY 2024 PRO FORMA ADJUSTED EBITDA MARGIN INCREASED TO
35-36%
FROM PREVIOUSLY APPROX 35%
* AN EXPECTED DIVIDEND PAYOUT RATIO OF 40-60%
Source text for Eikon: ID:nGNE272fX5
Further company coverage: NSISb.CO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Novozymes A/S
See all newsGivaudan jumps on fragrance outperformance; peers follow
Europe Research Roundup: IWG, Londonmetric, Sartorius
Brief: Novonesis To Build Next Generation Enzyme Production Facility In India
Next cycle in ingredient makers sector belongs to biotech, Jefferies says
Europe Research Roundup: DSM-Firmenich, Merck, Orsted